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Abstract 
Purpose: When codeine and tramadol are used for pain management, it is imperative that nurses are 
able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact 
drug metabolism and ultimately pain relief. Both drugs are metabolized through the CYP2D6 metabolic 
pathway which can be affected by medications as well the patient’s own pharmacogenotype. The 
purpose of this brief report is to identify drug-gene and drug-drug-gene interactions in 30 adult patients 
prescribed codeine or tramadol for pain. 
Methods: We used three data sources: (1) six months of electronic health record data on the number 
and types of medications prescribed to each patient; (2) each patient’s CYP2D6 pharmacogenotype, 
and (3) published data on known CYP2D6 gene-drug and drug-drug-gene interactions. 
Results: Ten patients (33%) had possible drug-gene or drug-drug-gene interactions. Five patients had 
CYP2D6 drug-gene interactions indicating they were not good candidates for codeine or tramadol. In 
addition, five patients had potential CYP2D6 drug-drug-gene interactions with either codeine or 
tramadol.  
Conclusion: Our findings from this exploratory study underscores the importance of assessing and 
accounting for drug-gene and drug-drug-gene interactions in patients prescribed codeine or tramadol.  
 
Keywords: Drug-gene interaction, drug-drug-gene interaction, pharmacogenomics, pharmacogenetic 
testing, opioid, pain management, polypharmacy 
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Drug-gene and drug-drug-gene interactions can interfere with patients’ abilities to metabolize 
codeine and tramadol for pain relief. Drug-gene interactions (DGIs) are defined as the influence of a 
patient’s genetic makeup on the ability to metabolize or clear a drug.1 Drug-drug-gene interactions 
(DDGIs) are defined as the effect of a patient’s genetic makeup and another medication in their 
regimen (e.g., cytochrome P450 inhibitor or inducer) on that patient’s ability to metabolize or clear a 
certain medication.1 A medication that is a cytochrome P450 inhibitor prevents the abilities of a drug 
metabolizing enzyme (e.g., CYP2D6) to metabolize a medication, whereas a medication that is an 
inducer increases the abilities of an enzyme to metabolize a medication.2 Therefore, DDGIs can alter a 
person’s drug metabolizing status (e.g., changing a person from a normal to a poor metabolizer) and 
increase the risk of adverse events such as treatment non-response or toxicity.3 Understanding both 
drug-gene and drug-drug-gene interactions are beneficial in predicting medication response. Current 
efforts to implement widespread pharmacogenetic testing in clinical practice require that nurses be 
knowledgeable about this field.4  
The goal of implementing pharmacogenetic testing in clinical practice is to help address wide 
interindividual variations in response to medication therapies. Ideally, this testing would lead to 
improved clinical and economic outcomes through avoidance of adverse drug effects and medication 
non-response.5-7 However, current clinical practice guidelines for pharmacogenetic testing account for 
drug-gene interactions but do not account for the complexity of patients’ medication regimens.8 
Polypharmacy, or the concurrent taking of multiple medications, may increase the potential for adverse 
drug effects or medication non-response as a result of known or unknown drug-drug-gene interactions.9 
For example, a person with a normal pharmacogenotype may not adequately metabolize a given 
medication if they are taking a concurrent medication that inhibits or induces the metabolic pathway for 
that given medication. While there is a paucity of research exploring drug-gene and drug-drug-gene 
interactions in the context of pain management, clinicians and researchers must consider the potential 
impact of both when evaluating the effects of codeine and tramadol for pain relief.  
 The purpose of this brief report was to identify drug-gene and drug-drug-gene interactions in 30 
adult patients prescribed codeine or tramadol for pain. Two pharmacogenetically actionable opioids 
(i.e., codeine and tramadol) were chosen as exemplar medications because they have evidence-based 
guidelines to guide drug or dosage changes based on pharmacogenetic test results.10  
Methods 
Design & Setting 
 This study was a retrospective analysis of 6-months of de-identified data from electronic health 
records (EHRs) and banked DNA specimens from a random selection of patients who were newly 
prescribed a pharmacogenetically actionable opioid in a primary care clinic within a large public health 
system that provides care for an underserved and low income population. Due to the de-identified 
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nature of this study, it was deemed non-human subjects research by the Office of Human Subjects 
Research. 
Sample 
 The sample included 30 patients randomly selected from the population of patients who met the 
following inclusion criteria: 1) part of a managed care program for individuals falling at or below 200 
percent of the federal poverty level, 2) first prescription of record for codeine or tramadol in at least one 
of the primary care clinics within the health system, 3) had a banked blood sample, 4) age 21 and older, 
and 5) had no documentation of substance abuse in the electronic health record. A ‘first prescription of 
record’ was defined as either codeine or tramadol being prescribed between January 1, 2010 and 
December 31, 2014 and no information in the patient’s record that indicated that either medication had 
been previously prescribed. 
Data & Procedures 
 Six months of EHR data for each patient were obtained from comprehensive data repositories. 
The 6-month time period started with the date of the new prescription for either codeine or tramadol and 
ended six months later. Data were accessed, extracted, and de-identified by a trained data analyst. The 
main repository where data originated was the Indiana Network for Patient Care, which is a large, multi-
institutional information exchange that captures EHR data from more than 25,000 individual providers, 
106 hospitals, and 110 clinics and surgery centers.11 The repository allows for capturing information 
about patients’ healthcare encounters across multiple clinics and health systems and information about 
medication orders and/or dispensing data from the safety-net health system, other health systems, and 
outpatient pharmacies within the region where this study was conducted. Other sources included 
clinical and administrative data repositories associated with the managed care program and public 
health system. The EHR data were linked to existing DNA specimens obtained from the biobank.  
 Patient characteristics and medication regimens. Demographic characteristics at the time of 
the new prescription for the pharmacogenetically actionable opioid were extracted from the EHR, 
including age, gender, and race. The medication regimen prescribed for each patient was identified 
through data elements including medication name, dose, dose frequency, route, administration 
instructions, and fill or refill dates. The mean number and range of medications prescribed per patient 
was determined over the 6-month time period. We also classified type of medication based on its 
indication (e.g., pain medications, cardiac medications, psychiatric medications, etc.) and calculated 
frequencies, mean number, and range of medications for that type.  
 CYP2D6 drug-gene interaction. A DGI occurs when the metabolization or clearance of a 
medication is influenced by a gene or genes.1 In this study, we identified the effects of a patient’s 
cytochrome P450 2D6 (CYP2D6) genotype on their ability to metabolize or clear codeine or tramadol. 
Both codeine and tramadol are considered prodrugs, meaning they are inactive and will not produce 
analgesic effects until metabolized into the active form of the drug. Therefore, we completed CYP2D6 
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genotype analyses on the banked DNA specimens for all patients in this study. The genotype results 
were then used to calculate the CYP2D6 enzyme activity score.10 The activity score is used to identify 
the drug metabolizing status (i.e., phenotype) classification and is determined by the sum of values 
assigned to each CYP2D6 star allele making up the diplotype.10 The drug metabolizing status 
classification includes ultra-rapid (activity score: >2), normal (activity score: 1-2), intermediate (activity 
score: 0.5), and poor (activity score: 0). The genotyping was performed for the CYP2D6 star alleles *2, 
*3, *4, *5, *6, *9, *10, *17, *29, and *41 using the QuantStudio (Thermo Fisher Scientific, Inc., Grand 
Island, NY) and following the manufacturer’s instructions of the Taqman Genotyping Assays (Applied 
Biosystems, Inc., Foster City, CA). These star alleles were chosen because they have common 
variants that influence both codeine and tramadol drug disposition and response, as well as their 
frequencies in Caucasian, African and their descendant populations.12 We completed quality controls 
for each sample batch and repeated assays for 20% of samples. We had a genotype call rate, defined 
as the proportion of genotypes per marker with non-missing data13, of 99.4%. This underscores the 
quality of our samples and genotyping procedures. 
 CYP2D6 drug-drug-gene interactions. A DDGI occurs when there is an interaction between 
an individual’s CYP2D6 genotype and a medication that affects a person’s ability to appropriately 
metabolize a different medication (e.g., codeine, tramadol).1 In this study, we identified a potential 
DDGI was present if two medications had known CYP2D6 interactions and that the supply amount 
dispensed for each medication overlapped. For example, if a 30-day supply of tramadol was dispensed 
10 days following a 60-day supply of fluoxetine being dispensed, we assumed that these two 
medications would be taken concurrently and coded these data as a DDGI present. The Flockhart 
TableTM for cytochrome P450 drug interactions served as the reference for identifying DDGIs in this 
sample (http://medicine.iupui.edu/clinpharm/ddis/main-table).2 
 To determine the effects of the DDGI on the CYP2D6 drug metabolizing status, we then 
adjusted the CYP2D6 enzyme activity score (identified from the CYP2D6 genotyping processes 
described above) for each patient based on identified DDGIs that would alter the CYP2D6 enzyme 
activity.2 For drug interactions with strong inhibitors of the opioid, the final activity score of 0 was 
assigned. For drug interactions with moderate inhibitors of the opioid, the CYP2D6 enzyme activity 
score was multiplied by 0.5 to identify the final activity score.14 Consequently, the drug metabolizing 
status for each patient was then determined from the final activity score.10 
Results 
  The sample consisted of 30 adults (16 female), of whom 60% were White and 40% were Black 
or Biracial. The mean age was 50.9 years (SD = 10.4; range = 23 – 65 years). The majority of patients 
were prescribed tramadol (n = 24), with fewer prescribed codeine (n = 6).  Patients received an average 
of 10 different medication prescriptions over the 6-month time period (range = 2-24). A mean of 3 
different pain medications were prescribed per patient, of which one was either codeine or tramadol per 
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inclusion criteria. Apart from the pain medications, the most common class of medications prescribed 
were for cardiovascular conditions (n = 23, 77% of sample), with 2.9 medications per patient for 
indications such as hypertension, dyslipidemia, and anticoagulation. In addition, 60% (n = 18) of the 
sample were prescribed medications for psychiatric problems such as depression or anxiety.  
 There were a total of 10 patients (33%) adversely affected by a DGI or DDGI. Adverse DGIs 
were present in 17% of the sample (n=5) (Table 1). Two patients were poor metabolizers, one patient 
an intermediate metabolizer, and two patients were considered ultra-rapid metabolizers. These patients 
would not be good candidates for codeine or tramadol due to the increased likelihood they would 
experience adverse drug effects or treatment non-response. The remaining patients were normal 
metabolizers (n=25) of the codeine or tramadol.  
 DDGIs were present in 17% of the sample (n=5) (Table 2). Based solely on the 
pharmacogenetic genotyping results, and not considering the effects of the DDGI on the patient’s 
CYP2D6 drug metabolizing status, all of these patients were initially considered normal metabolizers. 
However, the identified DDGIs involved either a strong (n = 4) or moderate inhibitor (n = 1) of the 
prescribed opioid, which altered patients’ CYP2D6 metabolizer status. As a result, four additional 
patients were ultimately classified as CYP2D6 poor metabolizers and one was classified as a CYP2D6 
intermediate metabolizer. 
Discussion 
 Findings from this exploratory study suggest that both drug-gene and drug-drug-gene 
interactions can be an issue in both clinical practice and research. Of note, 33 percent (n = 10) of our 
sample had altered CYP2D6 metabolizing status as a result of such interactions. Five different patients 
were identified with CYP2D6 drug-gene interactions and five additional patients were identified with 
potential CYP2D6 drug-drug-gene interactions with the pharmacogenetically actionable opioids. All 
interactions would result in altering their metabolizing status and result in no or decreased analgesia or 
enhanced side effects from tramadol or codeine.10 These findings are consistent with larger studies 
evaluating similar interactions.1, 9  
 Our findings highlight a number of clinical and research considerations. The fact that numerous 
patients in this study had altered CYP2D6 metabolizing status underscores the potential benefits of 
implementing pharmacogenetic testing in practice. Without determining these patients CYP2D6 
pharmacogenotype, these drug-gene and drug-drug-gene interactions would go undetected. In 
addition, this study provides important illustrations of why pharmacogenetic test results and complete 
medication regimens should be considered in tandem by nurses. Consequently, nurses need to 
consider drug-gene and drug-drug-gene interactions when assessing and educating patients about 
their medication regimens. Furthermore, future research is necessary to confirm and extend our 
findings. Studies that identify CYP2D6 drug-gene and drug-drug-gene interactions in a larger sample 
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and the impact of these interactions on patient outcomes (e.g., pain relief, adverse events) are 
warranted.  
Conclusion 
 The findings from this exploratory study underscore the importance of assessing and accounting 
for drug-gene and drug-drug-gene interactions in patients prescribed codeine or tramadol. We found 
that pharmacogenetic test results that identified drug-gene interactions were only part of the story and 
that the complexity of complete medication regimens added significantly to understanding patients’ 
abilities to appropriately metabolize these opioid medications. Therefore, future research and clinical 
guidelines must also account for potential for drug-drug-gene interactions.  
Table 1. Patients with Adverse Cytochrome P450 2D6 (CYP2D6) Drug-Gene Interactions 
CYP2D6 Drug 
Metabolizing 
Status 
Patient 
ID 
CYP2D6 
Diplotype 
CYP2D6 
Activity 
Score 
Prescribed 
PGxA Opioid 
Clinical Interpretation 
Poor 
Metabolizer 
12 *4/*5 0 Tramadol Patients are carrying no 
functional CYP2D6 alleles. 
Increased risk for lack of opioid 
efficacy. 
22 *4/*4 0 Codeine 
Intermediate 
Metabolizer 
21 *5/*41 0.5 Tramadol 
Patient carrying a reduced 
function CYP2D6 allele and a 
non-functional CYP2D6 allele. 
Increased risk for reduced 
opioid efficacy.  
Ultra-rapid 
Metabolizer 
5 *1/*17 >2 Tramadol 
Patients are carrying more 
than 2 copies of functional 
CYP2D6 alleles. Increased risk 
for potential opioid toxicity. 
17 *2/*2xN >2 Tramadol 
Note: This table only includes patients with adverse CYP2D6 drug-gene interactions and does not include 
patients (n = 25) who were considered to be normal CYP2D6 drug metabolizers. 
PGxA: pharmacogenetically actionable 
 
Table 2. Patients with Cytochrome P450 2D6 (CYP2D6) Drug-Drug-Gene Interactions & Clinical 
Interpretations 
Patient 
ID 
CYP2D6 
Diplotype 
CYP2D6 
Genotype 
Activity 
Score 
CYP2D6 DIs Final 
CYP2D6 
Activity 
Score 
Final 
CYP2D6 
Drug 
Metabolizing 
Status 
Clinical Interpretation 
07 *1/*41 
 
1.5 
 
Diphenhydramine
1
 – 
tramadol 
0 Poor 
Metabolizer 
Tramadol: Avoid 
medication due to lack 
of efficacy.  
11 *2/*5 1 Diphenhydramine
1
 – 
tramadol 
0 Poor 
Metabolizer 
Tramadol: Avoid 
medication due to lack 
of efficacy. 
16 *1/*5 1 Fluoxetine
1
 – tramadol 0 Poor 
Metabolizer 
Tramadol: Avoid 
medication due to lack 
of efficacy. 
19 *1/*4 1 Bupropion
1
 – codeine 0 Poor 
Metabolizer 
Codeine: Avoid 
medication due to lack 
of efficacy. 
23 *1/*4 1 Duloxetine
2
 – tramadol 0.5 Intermediate 
Metabolizer 
Tramadol: Avoid 
medication due to 
reduced efficacy. 
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DI: Drug interaction; 
1
 CYP2D6 strong inhibitor: Final CYP2D6 Activity Score = 0; 
2 
CYP2D6 moderate 
inhibitor: multiply CYP2D6 Genotype Activity Score by 0.5 to determine Final CYP2D6 Activity Score. 
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Highlights 
 CYP2D6 drug-gene and drug-drug-gene interactions can interfere with patients’ abilities to 
metabolize codeine and tramadol for pain relief. 
 33% of the sample were affected by a CYP2D6 drug-gene or drug-drug-gene interaction. 
 Findings suggest that both drug-gene and drug-drug-gene interactions can be an issue in both 
clinical practice and research. 
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